Lucinda Quan
Fondateur chez ALIGOS THERAPEUTICS, INC.
Fortune : 314 770 $ au 30/04/2024
Postes actifs de Lucinda Quan
Sociétés | Poste | Début | Fin |
---|---|---|---|
ALIGOS THERAPEUTICS, INC. | Fondateur | 05/02/2018 | - |
Conseiller Juridique Général | 01/03/2018 | - |
Historique de carrière de Lucinda Quan
Anciens postes connus de Lucinda Quan
Sociétés | Poste | Début | Fin |
---|---|---|---|
MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2016 | 01/04/2018 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Conseiller Juridique Général | 01/11/2013 | 01/01/2016 |
INTERMUNE INC | Conseiller Juridique Général | 01/09/2004 | 01/11/2013 |
Formation de Lucinda Quan
University of California, Los Angeles | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
General Counsel | 3 |
Founder | 1 |
Graduate Degree | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
ALIGOS THERAPEUTICS, INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- Lucinda Quan
- Expérience